Want to see CNTB full AI Analyst Report?
CNTB Stock Chart & Stats
$2.14
-$0.06(-2.73%)
At close: 4:00 PM EDT
$2.14
-$0.06(-2.73%)
Day’s Range― - ―
52-Week Range$1.23 - $3.82
Previous CloseN/A
Volume327.99K
Average Volume (3M)97.97K
Market Cap
$160.58M
Enterprise Value$118.77
Total Cash (Recent Filing)$31.49M
Total Debt (Recent Filing)$596.00K
Price to Earnings (P/E)―
Beta-0.13
Next Earnings
Nov 18, 2026EPS Estimate
-0.27Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.54
Shares Outstanding62,974,308
10 Day Avg. Volume111,495
30 Day Avg. Volume97,966
Financial Highlights & Ratios
PEG Ratio-0.01
Price to Book (P/B)3.74
Price to Sales (P/S)2452.52
P/FCF Ratio-3.04
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$7.29Price Target Upside240.45% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-7.45
Revenue Forecast (FY)$34.24M
Bulls Say, Bears Say
Bulls Say
Clinical Pipeline ProgressCompleting enrollment in two Phase 2 studies advances rademikibart toward meaningful efficacy and safety data. Positive topline results could support FDA engagement on Phase 3 development and materially strengthen the company’s pipeline.
Development RunwayA stated runway of at least one year gives the company time to obtain pivotal clinical data before requiring additional capital. This can reduce near-term execution pressure and support continued development of its lead program.
Low Debt BurdenVery low debt limits interest obligations and reduces refinancing risk compared with highly leveraged development companies. This provides some balance-sheet flexibility, although operating losses still make future funding needs important.
Bears Say
No Durable Product RevenueThe absence of 2025 revenue shows that the business has not established recurring commercial income. Until a therapy is approved or partnerships generate meaningful proceeds, operations remain dependent on clinical success and external financing.
Persistent Cash BurnDeeply negative operating and free cash flow indicate that clinical development consumes substantial capital without internally funding operations. Unless spending falls or revenue returns, continued funding transactions will remain structurally necessary.
Contracting Financial BaseFalling equity and assets reflect the cumulative effect of ongoing losses and reduce financial flexibility. A smaller capital base can increase dependence on future equity raises and heighten dilution or funding risk during development.
Connect Biopharma Holdings News
CNTB FAQ
What was Connect Biopharma Holdings’s price range in the past 12 months?
Connect Biopharma Holdings lowest stock price was $1.23 and its highest was $3.82 in the past 12 months.
What is Connect Biopharma Holdings’s market cap?
Connect Biopharma Holdings’s market cap is $160.58M.
When is Connect Biopharma Holdings’s upcoming earnings report date?
Connect Biopharma Holdings’s upcoming earnings report date is Nov 18, 2026 which is in 91 days.
How were Connect Biopharma Holdings’s earnings last quarter?
Connect Biopharma Holdings released its earnings results on Aug 12, 2026. The company reported -$0.27 earnings per share for the quarter, beating the consensus estimate of -$0.317 by $0.047.
Is Connect Biopharma Holdings overvalued?
According to Wall Street analysts Connect Biopharma Holdings’s price is currently Undervalued.
Does Connect Biopharma Holdings pay dividends?
Connect Biopharma Holdings does not currently pay dividends.
What is Connect Biopharma Holdings’s EPS estimate?
Connect Biopharma Holdings’s EPS estimate is -0.27.
How many shares outstanding does Connect Biopharma Holdings have?
Connect Biopharma Holdings has 62,974,308 shares outstanding.
What happened to Connect Biopharma Holdings’s price movement after its last earnings report?
Connect Biopharma Holdings reported an EPS of -$0.27 in its last earnings report, beating expectations of -$0.317. Following the earnings report the stock price went up 9.013%.
Which hedge fund is a major shareholder of Connect Biopharma Holdings?
Currently, no hedge funds are holding shares in CNTB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Connect Biopharma Holdings Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$7.29 (240.45% Upside)
$7.29 (240.45% Upside)
Insider Transactions
Bought Shares
Worth $370.5K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 4.4%
Last 30 Days ▲ 6.7%
Last 30 Days ▲ 6.7%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
39.51%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-47.45%
Trailing 12-Months
Company Description
Connect Biopharma Holdings
Connect Biopharma Holdings Limited is a clinical-stage biopharmaceutical company dedicated to discovering and advancing immune modulators. Its primary objective is to develop treatments for serious autoimmune diseases and various inflammatory conditions. The company's lead investigational therapy is CBP-201, an anti-interleukin-4 receptor alpha antibody. This candidate is currently in Phase IIb clinical trials, targeting inflammatory allergic diseases such as atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps. Additionally, Connect Biopharma's pipeline includes CBP-307, a small molecule designed to modulate sphingosine 1-phosphate receptor 1. This receptor plays a crucial role in regulating T cell movement from lymph nodes into the bloodstream. CBP-307 is in Phase II development for treating autoimmune-related inflammatory disorders. Another preclinical-stage asset, CBP-174, is an orally administered small molecule histamine receptor 3 antagonist, being investigated for chronic pruritus (itch) associated with skin inflammation. The portfolio also features CBP-233, a humanized antibody in preclinical development that targets interleukin-33, a cytokine recognized for its involvement in T helper 2 inflammation. Established in 2012, the company maintains its headquarters in Taicang, China.
CNTB Stock 12 Month Forecast
Average Price Target
$7.29
▲(240.45% Upside)
Technical Analysis
Scinai Immunotherapeutics
―
GT Biopharma
―
Revelation Biosciences
―
Dermata Therapeutics
―
CERo Therapeutics Holdings
―
Ownership Overview
21.29% Insiders
0.04% Mutual Funds
16.28% Other Institutional Investors
60.93% Public Companies and
Individual Investors